A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate the Diagnostic Efficacy and Safety of INR101 Injection for PET/CT Imaging in Detecting Preoperative Pelvic Lymph Node Metastasis in Patients With Prostate Cancer
Latest Information Update: 16 Apr 2025
At a glance
- Drugs INR-101 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use; Registrational
- Sponsors Yunhe Pharmaceutical (Tianjin)
Most Recent Events
- 16 Apr 2025 New trial record